- Patient Education: Video
NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research
Updated: Apr 7, 2022
NCI National Cancer Institute: Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research
![Immunotherapy CART Multiple Myeloma](https://static.wixstatic.com/media/cd6738_ce0f6714e488425699a44d652aa7e8b4~mv2.jpeg/v1/fill/w_147,h_105,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/cd6738_ce0f6714e488425699a44d652aa7e8b4~mv2.jpeg)
Manufacturing CAR T Cells to Accelerate Cancer Immunotherapy Research
An example of CART Cell therapy approved by FDA to treat relapsed & refractory Multiple Myeloma is